Colorectal Cancer Liver Metastases Clinical Trial
Official title:
PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
Capecitabine, oxaliplatin, irinotecan and bevacizumab as perioperative strategy of borderline and/or high risk resectable colorectal cancer liver metastases
Previous studies demonstrated a significant association between tumor regression grade of
hepatic colorectal metastases (TRG1: complete pathological response; TRG2: major pathological
response; TRG3: partial pathological response; versus TRG4-5 no pathological response) and
outcome in terms of survival after neoadjuvant treatment. In particular, retrospective data
showed an association between oxaliplatin-based chemotherapy and improvement of grade and
percentage of tumor regression; moreover, the addition of Bevacizumab seems to improve TRG
over chemotherapy alone, conferring also a protection against liver damage due to
chemotherapy-induced sinusoidal obstruction syndrome.
This is the rationale that induced us to carry out an evaluation and feasibility assessment
of a perioperative approach with COI-B regimen in patients affected by high risk or
borderline resectable colorectal liver metastases, with or without previous resection of
primary tumor.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05588297 -
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT04272931 -
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE
|
N/A | |
| Recruiting |
NCT05794971 -
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
|
Phase 3 | |
| Not yet recruiting |
NCT05873972 -
Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
|
N/A | |
| Recruiting |
NCT05485909 -
Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM
|
Phase 2 | |
| Active, not recruiting |
NCT03326791 -
Aspirin in Colorectal Cancer Liver Metastases
|
Phase 2/Phase 3 |